Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) ± strontium-89 (Sr89) in hormone-refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback